ABNX Stock Overview
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
ABIONYX Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.92|
|52 Week High||€3.57|
|52 Week Low||€0.90|
|1 Month Change||27.02%|
|3 Month Change||1.16%|
|1 Year Change||81.97%|
|3 Year Change||536.15%|
|5 Year Change||8.98%|
|Change since IPO||-84.44%|
Recent News & Updates
Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ABNX||FR Biotechs||FR Market|
Return vs Industry: ABNX exceeded the French Biotechs industry which returned -41.6% over the past year.
Return vs Market: ABNX exceeded the French Market which returned -5.8% over the past year.
|ABNX Average Weekly Movement||9.5%|
|Biotechs Industry Average Movement||6.7%|
|Market Average Movement||5.1%|
|10% most volatile stocks in FR Market||9.1%|
|10% least volatile stocks in FR Market||2.9%|
Stable Share Price: ABNX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ABNX's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of French stocks.
About the Company
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France.
ABIONYX Pharma Fundamentals Summary
|ABNX fundamental statistics|
Is ABNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABNX income statement (TTM)|
|Cost of Revenue||€416.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 29, 2022
|Earnings per share (EPS)||-0.21|
|Net Profit Margin||-862.52%|
How did ABNX perform over the long term?See historical performance and comparison
Is ABNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABNX?
Other financial metrics that can be useful for relative valuation.
|What is ABNX's n/a Ratio?|
Price to Book Ratio vs Peers
How does ABNX's PB Ratio compare to its peers?
|ABNX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ABNX ABIONYX Pharma
Price-To-Book vs Peers: ABNX is expensive based on its Price-To-Book Ratio (5x) compared to the peer average (1.7x).
Price to Earnings Ratio vs Industry
How does ABNX's PE Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Book vs Industry: ABNX is expensive based on its Price-To-Book Ratio (5x) compared to the French Biotechs industry average (2.5x)
Price to Book Ratio vs Fair Ratio
What is ABNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ABNX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ABNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ABNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ABNX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is ABIONYX Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABNX's revenue (63.6% per year) is forecast to grow faster than the French market (5.3% per year).
High Growth Revenue: ABNX's revenue (63.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has ABIONYX Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABNX is currently unprofitable.
Growing Profit Margin: ABNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABNX is unprofitable, but has reduced losses over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare ABNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).
Return on Equity
High ROE: ABNX has a negative Return on Equity (-54.53%), as it is currently unprofitable.
Discover strong past performing companies
How is ABIONYX Pharma's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ABNX's short term assets (€13.0M) exceed its short term liabilities (€6.7M).
Long Term Liabilities: ABNX's short term assets (€13.0M) exceed its long term liabilities (€4.4M).
Debt to Equity History and Analysis
Debt Level: ABNX has more cash than its total debt.
Reducing Debt: ABNX's debt to equity ratio has reduced from 48.2% to 21.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ABNX has less than a year of cash runway if free cash flow continues to grow at historical rates of 32% each year.
Discover healthy companies
What is ABIONYX Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABNX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cyrille Tupin (45 yo)
Sir Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Cyrille's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Insufficient data to compare Cyrille's compensation with company performance.
Experienced Management: ABNX's management team is considered experienced (3.6 years average tenure).
Experienced Board: ABNX's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.
ABIONYX Pharma SA's employee growth, exchange listings and data sources
- Name: ABIONYX Pharma SA
- Ticker: ABNX
- Exchange: ENXTPA
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €53.127m
- Shares outstanding: 27.70m
- Website: https://abionyx.com
Number of Employees
- ABIONYX Pharma SA
- 33 43 av. Georges Pompidou Bât. D2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/04 00:00|
|End of Day Share Price||2022/08/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.